Compare · BDX vs SRTS
BDX vs SRTS
Side-by-side comparison of Becton Dickinson and Company (BDX) and Sensus Healthcare Inc. (SRTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and SRTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $43.32B, about 667.9x SRTS ($64.9M).
- Over the past year, BDX is down 25.7% and SRTS is down 15.9% - SRTS leads by 9.8 points.
- BDX has been more active in the news (9 items in the past 4 weeks vs 5 for SRTS).
- BDX has more recent analyst coverage (25 ratings vs 8 for SRTS).
- Company
- Becton Dickinson and Company
- Sensus Healthcare Inc.
- Price
- $152.11-1.77%
- $3.98-0.75%
- Market cap
- $43.32B
- $64.9M
- 1M return
- -3.89%
- -5.69%
- 1Y return
- -25.68%
- -15.86%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 9
- 5
- Recent ratings
- 25
- 8
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Sensus Healthcare Inc.
Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sculptura product, a proprietary modulated robotic brachytherapy oncology therapy system that uses patented Beam Sculpting capabilities to treat various cancers during surgery; and Sentinel service program, which offers its customers protection for their systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
Latest BDX
- BD Earns Industry Top Honors for Transparency, Resiliency and Partnership
- Goldman resumed coverage on Becton Dickinson with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- BD to Announce Financial Results for its Second Quarter of Fiscal 2026
- Rick Byrd to Retire from BD
- For Women Managing Nighttime Incontinence, Better Sleep and Comfort Start with BD® PureWick® Urine Collection System
- BD Delivers Next‑Generation TIPS Innovation to Advance Portal Hypertension Care Across the European Union
- When Every Beat Matters, BD Helps Clinicians Eliminate Blind Spots with Continuous, Noninvasive Blood Pressure Insight
- SEC Form 4 filed by Neal Shana Carol
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest SRTS
- Sensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026
- Amendment: SEC Form 4 filed by Sachetta Eric
- Amendment: SEC Form 4 filed by Rampolla Javier
- Amendment: SEC Form 3 filed by new insider Martinez Magdalena
- Amendment: SEC Form 4 filed by Martinez Magdalena
- Sensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of Contract
- Alliance Global Partners initiated coverage on Sensus Healthcare with a new price target
- SEC Form 10-K filed by Sensus Healthcare Inc.
- Director Sachetta Eric bought $7,620 worth of shares (2,000 units at $3.81), increasing direct ownership by 1% to 142,113 units (SEC Form 4)
- Sensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed Base